ISSN: 1859 - 2872
Co-expression of some immunohistochemical markers of gastric adenocarcinoma
Main Article Content
Keywords
Abstract
Objective: To evaluate the co-expression of immunohistochemical markers HER2, CD44 and ALDH in gastric adenocarcinoma. Subject and method: A cross-sectional descriptive study; prospective design on 107 patients with confirmed diagnosis of gastric adenocarcinoma and surgical removal of the tumor at K Hospital. Evaluation of expression levels of markers HER2, CD44, ALDH in cancer samples and control samples. Result: The rate of gastric adenocarcinoma in men is higher than in women. The CD44 and HER2 co-expression rate was 15.9%. The rate of ALDH and HER2 co-expression was 18.7%. The rate of ALDH and CD44 co-expression was 43.9%. The expression rate of a single marker was 29.9%. Two markers simultaneously expressed the highest rate with 47.7%. The rate of expression of HER2, CD44 and ALDH concurrently was 10.3%. Conclusion: Immunohistochemical markers HER2, CD44, ALDH can be expressed alone or co-expressed in patients with gastric adenocarcinoma.
Article Details
References
2. Matsusaka S, Nashimoto A, Nishikawa K et al (2016) Clinicopathological factors associated with HER2 status in gastric cancer: Results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101). Gastric Cancer 19(3): 839-851.
3. Takaishi S, Okumura T, Tu S et al (2009) Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 27(5): 1006-1020.
4. Nguyen PH, Giraud J, Staedel C et al (2016) All-trans retinoic acid targets gastric cancer stem cells and inhibits patient-derived gastric carcinoma tumor growth. Oncogene 35(43): 5619-5628.
5. Smyth EC Verheij M, Allum W et al (2016) Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 27(5): 38-49.
6. Bao W, Fu HJ, Xie QS et al (2011) HER2 interacts with CD44 to up-regulate CXCR4 via epigenetic silencing of microRNA-139 in gastric cancer cells. Gastroenterology 141(6): 2076-2087.
7. Yang Z, Guo L, Liu D et al (2015) Acquisition of resistance to trastuzumab in gastric cancer cells is associated with activation of IL-6/STAT3/Jagged-1/Notch positive feedback loop. Oncotarget 6(7): 5072-5087.
8. Huang J, Li H, Ren G (2015) Epithelial-mesenchymal transition and drug resistance in breast cancer (Review). Int J Oncol 47(3): 840-848.
9. Kim YJ, Sung D, Oh E et al (2018) Flubendazole overcomes trastuzumab resistance by targeting cancer stem-like properties and HER2 signaling in HER2-positive breast cancer. Cancer Lett 412: 118-130.
10. Wakamatsu Y, Sakamoto N, Oo HZ et al (2012) Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer. Pathol Int 62(2): 112-119.
Article Sidebar
